Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
Neurogene Inc. (Nasdaq: NGNE) reported its first quarter 2024 financial results and highlighted recent corporate updates, focusing on the NGN-401 gene therapy trial for Rett syndrome. The company presented favorable safety data at the ASGCT Annual Meeting, received Australian HREC approval for the trial, and remains on track to provide interim efficacy data in Q4:24. Neurogene maintains a strong balance sheet with cash runway into 2H:26.
Positive financial results with cash, cash equivalents, and investments totaling $169.5 million as of March 31, 2024.
Expansion of NGN-401 trial with dosing the third patient, inclusion of additional patients and a high-dose cohort.
Favorable safety data presented at the ASGCT Annual Meeting with NGN-401 showing good tolerance.
Approval received to conduct the NGN-401 trial in Australia, enhancing the trial's reach.
Anticipated milestones include releasing interim efficacy data in Q4:24 and advancing an additional product candidate in 2025.
Increased R&D expenses of $13.5 million compared to $10.3 million in Q1 2023, driven by higher NGN-401 trial costs and preclinical expenses.
Rise in G&A expenses to $5.2 million from $2.8 million in Q1 2023, attributed to higher compensation, professional fees, and other costs.
Net loss of $16.9 million for Q1 2024, up from $12.3 million in Q1 2023, signaling a financial challenge.
Insights
Presented favorable safety data from Phase 1/2 NGN-401 gene therapy trial for Rett syndrome at ASGCT Annual Meeting
Received Australian HREC approval for
Remains on track to provide interim
Strong balance sheet with cash runway into 2H:26
“We have made substantial progress in our
Continued Dr. McMinn, “The
First Quarter 2024 and Recent Highlights, and Anticipated Milestones
Phase 1/2 Trial of
-
Presented favorable safety data from the first three pediatric patients in low-dose Cohort 1 at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting:
-
NGN-401 has been generally well-tolerated in all three patients with approximately nine, six and three months of follow-up, respectively - All treatment-related adverse events (AEs) have been mild/Grade 1, and all laboratory value changes are known risks of AAV administration and asymptomatic
- No signs or symptoms of MeCP2 overexpression toxicity reported in any patient, including Patient 1 who is nine months post-dosing and has a mild MECP2 variant predicted to result in residual MeCP2 expression
- No treatment-emergent or intracerebroventricular procedure-related serious AEs
-
-
Announced today acknowledgment from the Australian Therapeutic Goods Administration and approval from the Human Research Ethics Committee (HREC) to conduct the Phase 1/2 clinical trial for
NGN-401 inAustralia , the third region in which the trial is cleared - Continues to expect to report interim clinical data, including efficacy data from Cohort 1, in the fourth quarter of 2024; additional interim data, including from Cohort 2, are expected in the second half of 2025
-
Previously expanded the trial to include a high-dose Cohort 2 and more patients in low-dose Cohort 1; these updates are expected to generate a more complete data package and inform the design of a future
NGN-401 registrational study - Remains on track to complete enrollment in Cohort 1 in the second half of 2024 and to begin enrollment in Cohort 2 in the second quarter of 2024
Phase 1/2 Trial of
-
Continuing enrollment in high-dose Cohort 3, and plans to provide interim clinical data and a regulatory update in the second half of 2024; given the rarity of the disease,
U.S. Food and Drug Administration alignment on a streamlined registrational pathway will be critical for continued investment in the program
Additional Corporate Updates
- Advancing early-stage portfolio, and anticipates an additional product candidate using transgene regulation technology to enter the clinic in 2025
Upcoming Events
- 5th Annual Goldman Sachs Global Healthcare Conference: Management will provide a corporate presentation on June 12 at 1:20 p.m. ET and participate in 1x1 meetings
- 2024 IRSF (International Rett Syndrome Foundation) Rett Syndrome Scientific Meeting: Presentation of safety data from the Phase 1/2 NGN-401 gene therapy trial for Rett syndrome on June 18-19, 2024
First Quarter 2024 Financial Results
-
Cash Position: Cash, cash equivalents and investments as of March 31, 2024 were
. Cash outflows pertaining to the transaction with Neoleukin Therapeutics, including the offering costs associated with the pre-closing financing, were$169.5 million for the quarter ended March 31, 2024. The Company expects current cash, cash equivalents and marketable securities to fund operations into the second half of 2026.$9.6 million -
Research & Development (“R&D”) Expenses: R&D expenses were
for the three months ended March 31, 2024 compared to$13.5 million for the three months ended March 31, 2023. The increase in R&D expenses was primarily driven by an increase in$10.3 million NGN-401 clinical trial costs, increased preclinical costs related to our early discovery programs, and an increase in compensation and benefits expenses due to an increase in R&D headcount. -
General & Administrative (“G&A”) Expenses: G&A expenses were
for the three months ended March 31, 2024 compared to$5.2 million for the three months ended March 31, 2023. The increase in G&A expenses was primarily driven by an increase in compensation and benefits expenses due to an increase in G&A headcount, professional fees, insurance, information technology and other costs associated with becoming a public company.$2.8 million -
Net Loss: Net loss was
for the three months ended March 31, 2024 compared to net loss of$16.9 million for the three months ended March 31, 2023.$12.3 million
About Neurogene
The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release which are not historical in nature are intended to be, and hereby are identified as, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current expectations and beliefs of the management of Neurogene, as well as assumptions made by, and information currently available to, management of Neurogene, including, but not limited to, statements regarding: the therapeutic potential and utility, efficacy and clinical benefits of
This communication contains hyperlinks to information that is not deemed to be incorporated by reference into this communication.
- Financial Tables Follow -
Neurogene Inc. |
||||||
Condensed Consolidated Balance Sheets |
||||||
(In Thousands of |
||||||
|
|
|
|
|||
|
March 31, 2024 |
|
December 31, 2023 |
|||
Assets |
|
|
|
|||
Cash and cash equivalents |
$ |
150,140 |
|
$ |
148,210 |
|
Other current assets |
|
24,001 |
|
|
52,138 |
|
Non-current assets |
|
21,209 |
|
|
22,225 |
|
Total assets |
$ |
195,350 |
|
$ |
222,573 |
|
Liabilities |
|
|
|
|||
Current liabilities |
$ |
11,818 |
|
$ |
22,973 |
|
Non-current liabilities |
|
12,755 |
|
|
13,576 |
|
Total liabilities |
|
24,573 |
|
|
36,549 |
|
Stockholders' equity |
|
170,777 |
|
|
186,024 |
|
Total liabilities and stockholders' equity |
$ |
195,350 |
|
$ |
222,573 |
Neurogene Inc. |
||||||||
Condensed Consolidated Statements of Operations |
||||||||
(In thousands of |
||||||||
|
|
|
|
|||||
|
Three Months Ended |
|||||||
March 31, |
||||||||
|
2024 |
|
2023 |
|||||
Operating expenses: |
|
|
|
|||||
Research and development |
$ |
13,541 |
|
|
$ |
10,283 |
|
|
General and administrative |
|
5,238 |
|
|
|
2,752 |
|
|
Total operating expenses |
|
18,779 |
|
|
|
13,035 |
|
|
Loss from operations |
|
(18,779 |
) |
|
|
(13,035 |
) |
|
Other income, net |
|
1,858 |
|
|
|
772 |
|
|
Net loss |
$ |
(16,921 |
) |
|
$ |
(12,263 |
) |
|
|
|
|
|
|||||
Per share information: (1) |
|
|
|
|||||
Net loss per share, basic and diluted |
$ |
(1.00 |
) |
|
$ |
(28.28 |
) |
|
Weighted-average shares of common stock outstanding, basic and diluted |
16,903,735 |
433,623 |
||||||
|
|
|
|
|||||
(1) For the three months ended March 31, 2023, net loss per share information is presented for the Company’s then outstanding Class A common stock. For the three months ended March 31, 2024, net loss per share information is presented for the Company’s common stock. See Note 1, Reverse Merger and Pre-Closing Financing and Note 3, Net Loss Per Share Attributable to Common Stockholders, for additional information. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20240510025849/en/
Company:
Cara Mayfield
Vice President, Corporate Affairs
cara.mayfield@neurogene.com
Investors:
Melissa Forst
Argot Partners
Neurogene@argotpartners.com
Source: Neurogene Inc.
FAQ
What is the stock symbol of Neurogene Inc.?
What gene therapy program did Neurogene focus on in Q1 2024?
When is Neurogene expected to release interim efficacy data for NGN-401?